Solicitation Description

The purpose of this initiative is to partner with developers and other organizations to implement novel solutions to cGMP manufacturing hurdles and enable clinical trials for next-generation COVID-19 vaccines. The goal of these Project Awards is to advance innovative capabilities and improve the vaccine manufacturing enterprise to provide better COVID-19 solutions and bolster preparedness and response against future health security threats. Innovative technologies could encompass all aspects of manufacturing as well as analytical support, from excipients and other materials that may facilitate better production, to upstream and downstream processing, through final formulation.

Submission Information

A receipt confirmation will be provided by email. Offerors may submit, or re-submit, in advance of the deadline. Neither the Government nor the RRPV CMF will make allowances/exceptions for submission problems encountered by the Offeror using system-to-system interfaces. If the Offeror fails to submit the full submission prior to the deadline, the submission may not be accepted. It is the Offeror’s responsibility to ensure a timely and complete submission.

Solicitation Details

Q & A #2 Released:

Issued: 11 April 2024

Includes: Q&A #1-17

Q & A Released:

Issued: 18 March 2024

Includes: Q&A #1-16

Amendment 2:

Issued: 7 March 2024

Due: 19 April 2024 by 1pm Eastern

Changes: Extends the proposal due date from March 15, 2024 to April 19, 2024 at 1pm Eastern.

All other terms and conditions remain unchanged.

Amendment 1:

Issued: 8 February 2024

Due: 15 March 2024 by 1pm Eastern

Changes: Extends the question period in Section 6 from February 9, 2024 to February 23, 2024.

Original RPP Release:

Issued: 16 January 2024

Due: 15 March 2024 by 1pm Eastern

View the original RPP here